🇺🇸 FDA
Patent

US 11260050

Combination of cotinine plus antioxidant for treatment-resistant depression and correction of astrocytes functional deficit induced by depression and other neuropathological

granted A61KA61K31/202A61K31/4439

Quick answer

US patent 11260050 (Combination of cotinine plus antioxidant for treatment-resistant depression and correction of astrocytes functional deficit induced by depression and other neuropathological) held by United States Government as represented by the Department of Veterans Affairs expires Mon Feb 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
United States Government as represented by the Department of Veterans Affairs
Grant date
Tue Mar 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K31/202, A61K31/4439, A61K35/612, A61K45/06